FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079322523> ?p ?o ?g. }

• W2079322523 endingPage "1108" @default.
• W2079322523 startingPage "1102" @default.
• W2079322523 abstract "BACKGROUND The dysregulation of both myc gene expression and retinoid signaling pathways commonly occurs in small cell lung carcinoma (SCLC). Because preclinical data showed that all-trans-retinoic acid (RA) inhibited SCLC growth, altered myc expression, and blocked transition to a treatment-resistant phenotype, a Phase II trial was designed to determine the effects of the combination of RA, cisplatin, and etoposide in patients with SCLC. METHODS Patients with untreated, extensive stage SCLC were treated with up to 8 cycles of cisplatin, 60 mg/m2, intravenously (i.v.) on Day 1 and etoposide, 120 mg/m2, i.v. on Days 1-3 in addition to up to 1 year of oral RA, 150 mg/m2/day. RESULTS Of 22 assessable patients 1 had a complete response and 9 had a partial response, for an overall response rate of 45% (95% confidence interval, 24-68%). The median survival was 10.9 months and the 1-year survival was 41%. The median duration of chemotherapy was 6 cycles and the median duration of RA treatment was 2.8 months. Thirteen patients discontinued RA prematurely due to toxicity and only 4 responders were receiving RA at the time of recurrence. Toxicity-limiting RA treatment mainly was comprised of mucocutaneous changes and headaches. CONCLUSIONS RA at a dose of 150 mg/m2/day was tolerated poorly in combination with cisplatin plus etoposide, leading to early discontinuation of RA in the majority of patients. The hematologic toxicity, response rate, and survival were similar to those associated with cisplatin and etoposide in prior trials. Further studies with more active and less toxic agents will be required to determine the role of retinoids in the treatment of SCLC. Cancer 1998;83:1102-1108. © 1998 American Cancer Society." @default.
• W2079322523 created "2016-06-24" @default.
• W2079322523 creator A5002901761 @default.
• W2079322523 creator A5015924173 @default.
• W2079322523 creator A5019357584 @default.
• W2079322523 creator A5052461112 @default.
• W2079322523 creator A5059147930 @default.
• W2079322523 creator A5066306817 @default.
• W2079322523 date "1998-09-15" @default.
• W2079322523 modified "2023-10-12" @default.
• W2079322523 title "A Phase II study of all-trans-retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma" @default.
• W2079322523 cites W165108920 @default.
• W2079322523 cites W1660119080 @default.
• W2079322523 cites W1963786241 @default.
• W2079322523 cites W1965192518 @default.
• W2079322523 cites W1971365819 @default.
• W2079322523 cites W1994158531 @default.
• W2079322523 cites W2006930246 @default.
• W2079322523 cites W2018308993 @default.
• W2079322523 cites W2040029898 @default.
• W2079322523 cites W2058457903 @default.
• W2079322523 cites W2070059475 @default.
• W2079322523 cites W2087547963 @default.
• W2079322523 cites W2115874632 @default.
• W2079322523 cites W2123767004 @default.
• W2079322523 cites W2142710721 @default.
• W2079322523 cites W2168731357 @default.
• W2079322523 cites W2271048442 @default.
• W2079322523 cites W4293241248 @default.
• W2079322523 doi "https://doi.org/10.1002/(sici)1097-0142(19980915)83:6<1102::aid-cncr8>3.0.co;2-9" @default.
• W2079322523 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9740074" @default.
• W2079322523 hasPublicationYear "1998" @default.
• W2079322523 type Work @default.
• W2079322523 sameAs 2079322523 @default.
• W2079322523 citedByCount "31" @default.
• W2079322523 countsByYear W20793225232012 @default.
• W2079322523 countsByYear W20793225232013 @default.
• W2079322523 countsByYear W20793225232014 @default.
• W2079322523 countsByYear W20793225232015 @default.
• W2079322523 countsByYear W20793225232018 @default.
• W2079322523 countsByYear W20793225232023 @default.
• W2079322523 crossrefType "journal-article" @default.
• W2079322523 hasAuthorship W2079322523A5002901761 @default.
• W2079322523 hasAuthorship W2079322523A5015924173 @default.
• W2079322523 hasAuthorship W2079322523A5019357584 @default.
• W2079322523 hasAuthorship W2079322523A5052461112 @default.
• W2079322523 hasAuthorship W2079322523A5059147930 @default.
• W2079322523 hasAuthorship W2079322523A5066306817 @default.
• W2079322523 hasBestOaLocation W20793225231 @default.
• W2079322523 hasConcept C126322002 @default.
• W2079322523 hasConcept C143998085 @default.
• W2079322523 hasConcept C2776256026 @default.
• W2079322523 hasConcept C2776694085 @default.
• W2079322523 hasConcept C2778119113 @default.
• W2079322523 hasConcept C2778239845 @default.
• W2079322523 hasConcept C2778715236 @default.
• W2079322523 hasConcept C29730261 @default.
• W2079322523 hasConcept C31760486 @default.
• W2079322523 hasConcept C71924100 @default.
• W2079322523 hasConcept C90924648 @default.
• W2079322523 hasConceptScore W2079322523C126322002 @default.
• W2079322523 hasConceptScore W2079322523C143998085 @default.
• W2079322523 hasConceptScore W2079322523C2776256026 @default.
• W2079322523 hasConceptScore W2079322523C2776694085 @default.
• W2079322523 hasConceptScore W2079322523C2778119113 @default.
• W2079322523 hasConceptScore W2079322523C2778239845 @default.
• W2079322523 hasConceptScore W2079322523C2778715236 @default.
• W2079322523 hasConceptScore W2079322523C29730261 @default.
• W2079322523 hasConceptScore W2079322523C31760486 @default.
• W2079322523 hasConceptScore W2079322523C71924100 @default.
• W2079322523 hasConceptScore W2079322523C90924648 @default.
• W2079322523 hasIssue "6" @default.
• W2079322523 hasLocation W20793225231 @default.
• W2079322523 hasLocation W20793225232 @default.
• W2079322523 hasOpenAccess W2079322523 @default.
• W2079322523 hasPrimaryLocation W20793225231 @default.
• W2079322523 hasRelatedWork W2017316579 @default.
• W2079322523 hasRelatedWork W2055244776 @default.
• W2079322523 hasRelatedWork W2077334567 @default.
• W2079322523 hasRelatedWork W2100029565 @default.
• W2079322523 hasRelatedWork W2413020017 @default.
• W2079322523 hasRelatedWork W2414573978 @default.
• W2079322523 hasRelatedWork W363598932 @default.
• W2079322523 hasRelatedWork W4206600817 @default.
• W2079322523 hasRelatedWork W4246355098 @default.
• W2079322523 hasRelatedWork W8414141 @default.
• W2079322523 hasVolume "83" @default.
• W2079322523 isParatext "false" @default.
• W2079322523 isRetracted "false" @default.
• W2079322523 magId "2079322523" @default.
• W2079322523 workType "article" @default.